ES2073177T3 - Formulados bifasicos para la liberacion de farmacos lipofilos. - Google Patents
Formulados bifasicos para la liberacion de farmacos lipofilos.Info
- Publication number
- ES2073177T3 ES2073177T3 ES91918238T ES91918238T ES2073177T3 ES 2073177 T3 ES2073177 T3 ES 2073177T3 ES 91918238 T ES91918238 T ES 91918238T ES 91918238 T ES91918238 T ES 91918238T ES 2073177 T3 ES2073177 T3 ES 2073177T3
- Authority
- ES
- Spain
- Prior art keywords
- pct
- active substance
- fatty acid
- date
- pharmaceutically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
- Professional, Industrial, Or Sporting Protective Garments (AREA)
- Laminated Bodies (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
UNA FORMULACION FARMACEUTICA COMPRENDE: (A) UN C12 ACIDO GRASO, QUE PUEDE SER NO SATURADO O MONOSATURADO O POLISATURADO, TAL COMO ACIDO OLEICO O LINOLEICO; (B) UNA SUSTANCIA ACTIVA FARMACEUTICAMENTE Y DE FORMA GENERAL LIPOFILICA. UNA PORCION DE C12 ON NO SOSTENIDA SOBRE ADMINISTRACION NO PARENTERAL Y UNA PORCION DEL C12 ANCIA ACTIVA FARMACEUTICAMENTE ESTAN FORMULADAS COMO LIBERACION SOSTENIDA EN ADMINISTRACION NO PARENTERAL. LA SUSTANCIA ACTIVA FARMACEUTICAMENTE PUEDE SER UN MEDICAMENTO CARDIOVASCULAR TAL COMO PROPRANOLOL, VERAPAMIL, NIFEDIPINE, DILTIAZEM, METOPROLOL, NICARDIPINE O LABETOLOL. TALES FORMULACIONES PROMUEVEN UNA REDISTRIBUCION DE ABSORCION DE LA SUSTANCIA(S) ACTIVAS DESDE EL SUMINISTRO DE SANGRE PORTAL HEPATICA AL SISTEMA LINFATICO, DE AQUI SE EVITA EN UN PRIMER PASO EL METABOLISMO DEL HIGADO. FORMULACIONES DE ESTE TIPO TENDRAN UNA DOSIS PREDICTABLE COMO RESPUESTA EN PACIENTES, CONSEGUIDA CON UNA CARGA QUIMICA MAS BAJA, CON LA QUE LA EFICACIA TERAPEUTICA SE MANTIENE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909022788A GB9022788D0 (en) | 1990-10-19 | 1990-10-19 | Pharmaceutical formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2073177T3 true ES2073177T3 (es) | 1995-08-01 |
Family
ID=10684032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES91918238T Expired - Lifetime ES2073177T3 (es) | 1990-10-19 | 1991-10-18 | Formulados bifasicos para la liberacion de farmacos lipofilos. |
Country Status (21)
Country | Link |
---|---|
US (1) | US5391377A (es) |
EP (1) | EP0553178B1 (es) |
JP (1) | JP3276368B2 (es) |
KR (1) | KR100188642B1 (es) |
AT (1) | ATE122881T1 (es) |
AU (1) | AU656924B2 (es) |
BG (1) | BG61383B1 (es) |
CA (1) | CA2093206C (es) |
CZ (1) | CZ282822B6 (es) |
DE (1) | DE69110052T2 (es) |
DK (1) | DK0553178T3 (es) |
ES (1) | ES2073177T3 (es) |
FI (1) | FI104408B (es) |
GB (1) | GB9022788D0 (es) |
HK (1) | HK85296A (es) |
HU (2) | HUT64215A (es) |
NO (1) | NO305505B1 (es) |
RO (1) | RO114739B1 (es) |
RU (1) | RU2121344C1 (es) |
SK (1) | SK279845B6 (es) |
WO (1) | WO1992006680A1 (es) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
GB9325445D0 (en) * | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5430021A (en) * | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
DE4443175A1 (de) * | 1994-12-05 | 1996-06-13 | Jenapharm Gmbh | Neue pulsatile Arzneiform |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
AU4862796A (en) * | 1995-02-06 | 1996-08-27 | Nanosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
CA2224227A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US6024980A (en) * | 1996-06-28 | 2000-02-15 | Mcneil-Ppc, Inc. | Multiphase soft gelatin dosage form |
US6093420A (en) | 1996-07-08 | 2000-07-25 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US20030008919A1 (en) * | 1999-06-03 | 2003-01-09 | Jean-Baptiste Roullet | Use of retinoids to treat high blood pressure and other cardiovascular disease |
JP2002500190A (ja) | 1998-01-08 | 2002-01-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 海洋海綿から誘導されるキネシンモーターモジュレーター |
US7030155B2 (en) * | 1998-06-05 | 2006-04-18 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
FR2782006B1 (fr) * | 1998-08-07 | 2002-04-19 | Gattefosse Ets Sa | Composition a liberation prolongee apte a former une micro-emulsion |
KR100602725B1 (ko) | 1998-12-11 | 2006-07-20 | 파마솔루션스, 인코포레이티드 | 물에서 불충분하게 용해되는 약제를 위한 자가-유화용조성물 |
US6057289A (en) * | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
CA2409437A1 (en) * | 2000-05-11 | 2001-11-22 | Pharmacia Corporation | Aldosterone antagonist composition for release during aldosterone acrophase |
US8568766B2 (en) * | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
CN100553625C (zh) * | 2002-04-09 | 2009-10-28 | 弗拉梅技术公司 | 活性成分微囊的口服混悬液 |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US20040005359A1 (en) * | 2002-06-27 | 2004-01-08 | Cheng Xiu Xiu | Controlled release oral dosage form |
US20040077621A1 (en) * | 2002-08-08 | 2004-04-22 | Academia Sinica | Antioxidants |
EP1594512A4 (en) * | 2003-02-11 | 2007-07-11 | Kemia Inc | COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS |
US7314640B2 (en) * | 2003-07-11 | 2008-01-01 | Mongkol Sriwongjanya | Formulation and process for drug loaded cores |
CA2552887A1 (en) * | 2004-01-14 | 2005-07-28 | Lavipharm Laboratories, Inc. | Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid |
US20060003001A1 (en) * | 2004-02-11 | 2006-01-05 | John Devane | Chronotherapeutic compositions and methods of their use |
EP1766389A4 (en) | 2004-05-12 | 2008-08-27 | Inst Medical W & E Hall | CELL ISOLATION PROCEDURE |
US8648045B2 (en) | 2005-03-10 | 2014-02-11 | Ben Gurion University Of The Negev Research And Development Authority Ltd. | VDAC1 compositions and methods of use thereof for regulating apoptosis |
US8119601B2 (en) * | 2005-03-10 | 2012-02-21 | Ben-Gurion University Of The Negev Research And Development Authority Ltd. | Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis |
MX2007013430A (es) | 2005-04-29 | 2008-03-19 | Univ California | Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria. |
WO2006135985A1 (en) | 2005-06-24 | 2006-12-28 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same |
US8691272B2 (en) * | 2005-12-30 | 2014-04-08 | Intelgenx Corp. | Multilayer tablet |
NZ569697A (en) | 2006-01-20 | 2012-01-12 | Women S & Children S Health Res Inst | Method of treatment, prophylaxis and diagnosis of pathologies of the bone by the modulation of GPC3 |
US8440788B2 (en) * | 2006-04-06 | 2013-05-14 | Ben-Gurion University Of The Negev Research And Development Authority Ltd. | N-terminal VDAC variants and uses thereof |
WO2007123153A1 (ja) * | 2006-04-19 | 2007-11-01 | Ono Pharmaceutical Co., Ltd. | 経口投与用カプセル |
MY153288A (en) * | 2006-06-28 | 2015-01-29 | Hovid Berhad | An effective pharmaceutical carrier for poorly bioavailable drugs |
JP5300477B2 (ja) * | 2006-08-01 | 2013-09-25 | 大塚製薬株式会社 | 薬理活性物質の吸収性が改善された医薬組成物 |
AU2007309408A1 (en) * | 2006-10-27 | 2008-05-02 | Janssen Pharmaceutica N.V. | Dry granulated pharmaceutical compositions and methods for producing same |
EP2167528B1 (en) * | 2007-06-21 | 2018-01-10 | Angelica Therapeutics, INC. | Modified toxins |
ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
AU2008296478B9 (en) * | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
SI2205245T1 (sl) * | 2007-10-03 | 2015-10-30 | Wista Laboratories Ltd. | Terapevtska uporaba diaminofenotiazinov |
WO2009110944A1 (en) | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
CA2722271C (en) * | 2008-05-12 | 2013-08-06 | Hilde Buydts | Improved capsule with air-vents |
US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
CN102711809B (zh) | 2009-08-17 | 2015-09-30 | 特雷康制药公司 | 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症 |
US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
ES2363965B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm S.A. | Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados. |
US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
US20110136815A1 (en) | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
US9249189B2 (en) | 2010-01-18 | 2016-02-02 | Albany Medical College | Alpha-fetoprotein “ring and tail” peptides |
JP5878538B2 (ja) | 2010-08-27 | 2016-03-08 | ギリアド バイオロジクス, インク.Gilead Biologics, Inc. | マトリクスメタロプロティナーゼ9に対する抗体 |
EP2627349B1 (en) | 2010-10-15 | 2016-02-03 | The Trustees of Columbia University in the City of New York | Obesity-related genes and their proteins and uses thereof |
AU2012249301A1 (en) | 2011-04-29 | 2013-11-21 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
JP6368645B2 (ja) | 2011-09-29 | 2018-08-01 | ピーエルエックス オプコ インコーポレーテッド | 胃腸管に沿った医薬の標的化放出のためのpH依存性担体、それによる組成物、ならびにこれらの製造および使用 |
CA2865530C (en) | 2012-02-29 | 2019-02-19 | Gilead Biologics, Inc. | Antibodies to matrix metalloproteinase 9 |
MD20140108A2 (ro) | 2012-02-29 | 2015-03-31 | Gilead Biologics, Inc. | Anticorpi împotriva metaloproteinazei 9 matriciale |
WO2013128453A1 (en) | 2012-03-01 | 2013-09-06 | Yeda Research And Development Co. Ltd. | Regeneration of islet beta cells by hsp60 derived peptides |
US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
TW201406707A (zh) | 2012-05-04 | 2014-02-16 | Acucela Inc | 用以治療糖尿病性視網膜病變及其他眼部疾病之方法 |
CA2879427A1 (en) | 2012-07-20 | 2014-01-23 | La Trobe University | Method of diagnosis and treatment |
UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
MX2015012818A (es) | 2013-03-14 | 2016-05-12 | Uab Research Foundation | Mimeticos de apolipoproteina y usos de los mismos. |
EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
WO2014152006A2 (en) | 2013-03-15 | 2014-09-25 | Intrinsic Lifesciences, Llc | Anti-hepcidin antibodies and uses thereof |
CN105050614B (zh) | 2013-03-15 | 2019-04-05 | 加利福尼亚大学董事会 | 刺激胆固醇流出的具有降低的毒性的肽 |
US9758559B2 (en) | 2013-07-25 | 2017-09-12 | B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Short peptides derived from VDAC1, compositions and methods of use thereof |
EP3083672A1 (en) | 2013-12-20 | 2016-10-26 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Pro-angiogenic peptides and peptide conjugates |
KR20160125466A (ko) | 2014-02-27 | 2016-10-31 | 길리애드 사이언시즈, 인코포레이티드 | 매트릭스 메탈로프로테이나제 9에 대한 항체 및 그의 사용 방법 |
US20150361182A1 (en) | 2014-06-11 | 2015-12-17 | Gilead Sciences, Inc. | Methods for treating cardiovascular diseases |
US10793614B2 (en) | 2014-07-17 | 2020-10-06 | Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. | Antagonists of fish reproduction |
EP3169700A1 (en) | 2014-07-17 | 2017-05-24 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Antagonists of neurokinin b in fish reproduction |
CN107074923B (zh) | 2014-07-31 | 2021-08-03 | Uab研究基金会 | Apoe模拟肽及对清除血浆胆固醇的较高效力 |
WO2016019333A1 (en) | 2014-07-31 | 2016-02-04 | Kinemed, Inc. | The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties |
CA2961917A1 (en) | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
JP6877419B2 (ja) | 2015-10-27 | 2021-05-26 | ザ ユニバーシティー オブ クイーンズランド | 治療の方法およびそのために有用な剤 |
US11034739B2 (en) | 2015-11-13 | 2021-06-15 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada | Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases |
US20170174788A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
AU2017248354A1 (en) | 2016-04-08 | 2018-10-04 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
US11154591B2 (en) | 2016-10-14 | 2021-10-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating alcohol abuse disorder |
CA3051897A1 (en) | 2017-01-30 | 2018-08-02 | Hudson Institute of Medical Research | A method of treatment |
WO2018213803A1 (en) | 2017-05-19 | 2018-11-22 | Neon Therapeutics, Inc. | Immunogenic neoantigen identification |
KR102484433B1 (ko) | 2017-11-08 | 2023-01-03 | 바이오엔테크 유에스 인크. | T 세포 제조 조성물 및 방법 |
WO2020252208A2 (en) | 2019-06-11 | 2020-12-17 | Myeloid Therapeutics, Inc. | Macrophage specific engager compositions and methods of use thereof |
WO2020252039A1 (en) | 2019-06-12 | 2020-12-17 | Biontech Us Inc. | Neoantigen compositions and uses thereof |
JP2023518822A (ja) | 2020-03-26 | 2023-05-08 | ピーエルエックス オプコ インコーポレイテッド | pH依存的再構築が可能な医薬キャリア、その製造方法及び使用方法 |
IL300564A (en) | 2020-08-13 | 2023-04-01 | Biontech Us Inc | Preparations and methods for the production of T cells |
JP2023549140A (ja) | 2020-11-04 | 2023-11-22 | マイエロイド・セラピューティクス,インコーポレーテッド | 操作されたキメラ融合タンパク質組成物およびその使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1600639A (en) * | 1978-05-23 | 1981-10-21 | Kali Chemie Pharma Gmbh | Medicament preparation having resorption properties and method of producing the same |
US4916230A (en) * | 1984-07-02 | 1990-04-10 | Merck & Co., Inc. | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
US4946870A (en) * | 1986-06-06 | 1990-08-07 | Union Carbide Chemicals And Plastics Company Inc. | Delivery systems for pharmaceutical or therapeutic actives |
IT1200178B (it) * | 1986-07-23 | 1989-01-05 | Alfa Farmaceutici Spa | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica |
US5229422A (en) * | 1987-09-07 | 1993-07-20 | Teijin Limited | Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion |
EP0351897A3 (en) * | 1988-06-17 | 1990-03-21 | The Procter & Gamble Company | Skin penetration system for salts of amine-functional drugs |
GB8822857D0 (en) * | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
GB8909022D0 (en) * | 1989-04-20 | 1989-06-07 | Cortecs Ltd | Pharmaceutical compositions |
-
1990
- 1990-10-19 GB GB909022788A patent/GB9022788D0/en active Pending
-
1991
- 1991-10-18 SK SK363-93A patent/SK279845B6/sk unknown
- 1991-10-18 KR KR1019930701127A patent/KR100188642B1/ko not_active IP Right Cessation
- 1991-10-18 AT AT91918238T patent/ATE122881T1/de not_active IP Right Cessation
- 1991-10-18 ES ES91918238T patent/ES2073177T3/es not_active Expired - Lifetime
- 1991-10-18 CZ CZ93641A patent/CZ282822B6/cs not_active IP Right Cessation
- 1991-10-18 JP JP51690491A patent/JP3276368B2/ja not_active Expired - Fee Related
- 1991-10-18 WO PCT/GB1991/001824 patent/WO1992006680A1/en active IP Right Grant
- 1991-10-18 DK DK91918238.6T patent/DK0553178T3/da active
- 1991-10-18 RU RU93048157A patent/RU2121344C1/ru active
- 1991-10-18 AU AU87315/91A patent/AU656924B2/en not_active Ceased
- 1991-10-18 US US08/050,064 patent/US5391377A/en not_active Expired - Lifetime
- 1991-10-18 RO RO93-00534A patent/RO114739B1/ro unknown
- 1991-10-18 EP EP91918238A patent/EP0553178B1/en not_active Expired - Lifetime
- 1991-10-18 HU HU9301121A patent/HUT64215A/hu unknown
- 1991-10-18 DE DE69110052T patent/DE69110052T2/de not_active Expired - Fee Related
- 1991-10-18 CA CA002093206A patent/CA2093206C/en not_active Expired - Fee Related
-
1993
- 1993-04-16 FI FI931745A patent/FI104408B/fi active
- 1993-04-16 NO NO931410A patent/NO305505B1/no not_active IP Right Cessation
- 1993-04-16 BG BG97644A patent/BG61383B1/bg unknown
-
1995
- 1995-06-30 HU HU95P/P00725P patent/HU211617A9/hu unknown
-
1996
- 1996-05-16 HK HK85296A patent/HK85296A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0553178A1 (en) | 1993-08-04 |
CA2093206A1 (en) | 1992-04-20 |
JPH06502143A (ja) | 1994-03-10 |
ATE122881T1 (de) | 1995-06-15 |
CA2093206C (en) | 2002-01-29 |
BG61383B1 (en) | 1997-07-31 |
NO305505B1 (no) | 1999-06-14 |
HUT64215A (en) | 1993-12-28 |
SK279845B6 (sk) | 1999-04-13 |
HU9301121D0 (en) | 1993-07-28 |
RO114739B1 (ro) | 1999-07-30 |
US5391377A (en) | 1995-02-21 |
FI104408B (fi) | 2000-01-31 |
KR100188642B1 (ko) | 1999-06-01 |
DK0553178T3 (da) | 1995-07-24 |
HU211617A9 (en) | 1995-12-28 |
NO931410L (no) | 1993-04-16 |
SK36393A3 (en) | 1993-07-07 |
FI931745A (fi) | 1993-04-16 |
DE69110052T2 (de) | 1995-10-05 |
NO931410D0 (no) | 1993-04-16 |
CZ64193A3 (en) | 1994-01-19 |
DE69110052D1 (de) | 1995-06-29 |
JP3276368B2 (ja) | 2002-04-22 |
EP0553178B1 (en) | 1995-05-24 |
BG97644A (bg) | 1994-04-29 |
AU656924B2 (en) | 1995-02-23 |
CZ282822B6 (cs) | 1997-10-15 |
HK85296A (en) | 1996-05-24 |
AU8731591A (en) | 1992-05-20 |
GB9022788D0 (en) | 1990-12-05 |
FI931745A0 (fi) | 1993-04-16 |
KR930701989A (ko) | 1993-09-08 |
RU2121344C1 (ru) | 1998-11-10 |
WO1992006680A1 (en) | 1992-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2073177T3 (es) | Formulados bifasicos para la liberacion de farmacos lipofilos. | |
RU93048157A (ru) | Фармацевтическая композиция двухфазного действия с высвобождением для липофильных лекарственных препаратов, способ ее получения, применение композиции для лечения заболеваний | |
Pastore et al. | Transdermal patches: history, development and pharmacology | |
AR012854A1 (es) | Una composicion de suministro de droga para la liberacion controlada de un ingrediente activo en el ambiente estomacal por un periodo de tiempoprolongado, una composicion farmaceutica que la comprende, el uso de dicha composicion en la fabricacion de un medicamento, un proceso para la preparacion | |
JP2009515910A5 (es) | ||
US20100016436A1 (en) | Transdermal Administration of Active Agents, in Particular Diclofenac | |
US20040202705A1 (en) | Transdermal administration of huperzine | |
JP4624673B2 (ja) | 化合物の経皮輸送 | |
IT1200178B (it) | Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica | |
DK1341527T3 (da) | Farmaceutisk præparat omfattende et aktivstof dispergeret på en matrix | |
PT1256339E (pt) | Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina | |
ATE522211T1 (de) | Stabilisierte fibrat-mikropartikel | |
ATE235234T1 (de) | Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerte freisetzung | |
ATE202926T1 (de) | Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung | |
GEP20053455B (en) | Pharmaceutical Preparations | |
JP2022551696A (ja) | 発作性障害の治療用のカンナビジオール(cbd)を含む経皮医薬組成物 | |
US8404745B2 (en) | Transdermal delivery of medicinal cetylated fatty esters using phonophoresis or iontophoresis | |
Benson et al. | Optimisation of Drug Delivery: 4. Transdermal Drug Delivery | |
DE69803772D1 (de) | Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung | |
JP2002520269A5 (es) | ||
GEP20063804B (en) | Once-a-day oxycodone formulations | |
DE59908258D1 (de) | Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform | |
UA86516C2 (ru) | Ветеринарная биологически активная добавка липосомальной формы и способ репаративной терапии в гепатологии | |
JPS61243016A (ja) | 柱状の有効成分含有部分をもつ錠剤 | |
TH32076B (th) | รูปขนาดใช้ยางทางเภสัชกรรมสำหรับให้ทางปากซึ่งประกอบด้วยสารยับยั้งการดึงโปรตอน และสารโปรไคเนนทิค |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 553178 Country of ref document: ES |